Back

Anti-tumor effects of an Id antagonist with no acquired resistance

Wojnarowicz, P. M.; Escalono, M. G.; Huang, Y.-H.; Desai, B.; Chin, Y.; Shah, R.; Xu, S.; Ouerfelli, O.; Soni, R. K.; Philip, J.; Montrose, D. C.; Healey, J. H.; Rajasekhar, V. K.; Garland, W. A.; Norton, L.; Rosen, N.; Hendrickson, R. C.; Zhou, X. K.; Iavarone, A.; Massague, J.; Dannenberg, A. J.; Lasorella, A.; Benezra, R.

2020-01-06 cancer biology
10.1101/2020.01.06.894840 bioRxiv
Show abstract

Id proteins are helix-loop-helix (HLH) transcriptional regulators frequently overexpressed in cancer. Id proteins inhibit basic HLH transcription factors through protein-protein interactions, often inhibiting differentiation and sustaining proliferation. We recently identified a small-molecule, AGX51, which targets Id proteins for degradation and impairs ocular neovascularization in mouse models. Here we show that AGX51 treatment of cancer cell lines impaired cell growth and viability that results from a dramatic increase in ROS production upon Id degradation. In mouse models, AGX51 treatment suppressed breast cancer colonization in the lung, regressed the growth of paclitaxel-resistant breast tumors when combined with paclitaxel and reduced tumor burden in a model of sporadic colorectal neoplasia. Furthermore, in cells and mice, we failed to observe acquired resistance to AGX51 likely the result of the immutability of the binding pocket and efficient degradation of the Id proteins. Thus, AGX51 is a first-in-class compound that antagonizes Id proteins, shows strong anti-tumor effects and may be further developed for the management of multiple cancers.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cell Reports
○ 1498 papers in training set
Top 0.3%
18.1%
Similar papers in this journal
2
eLife
● 5828 papers in training set
Top 11%
9.5%
Similar papers in this journal
3
Cancer Research
● 130 papers in training set
Top 0.5%
6.1%
Similar papers in this journal
4
Oncogene
○ 85 papers in training set
Top 0.3%
5.4%
Similar papers in this journal
5
iScience
○ 1154 papers in training set
Top 3%
4.7%
Similar papers in this journal
6
Cancers
○ 213 papers in training set
Top 1%
4.3%
7
Cancer Research Communications
● 51 papers in training set
Top 0.2%
4.0%
50% of probability mass above
8
Molecular Cancer Research
● 49 papers in training set
Top 0.2%
4.0%
9
Disease Models & Mechanisms
139 papers in training set
Top 0.6%
3.4%
10
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.3%
3.2%
11
Nature Communications
○ 5641 papers in training set
Top 37%
3.1%
12
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 19%
2.7%
13
Cell Chemical Biology
○ 94 papers in training set
Top 0.6%
2.1%
14
Scientific Reports
○ 3612 papers in training set
Top 47%
2.1%
15
EMBO Reports
○ 263 papers in training set
Top 3%
2.1%
16
Cancer Letters
○ 35 papers in training set
Top 0.5%
1.9%
17
Science Signaling
● 65 papers in training set
Top 1%
1.1%
18
EMBO Molecular Medicine
○ 95 papers in training set
Top 2%
1.1%
19
Cell Reports Medicine
○ 153 papers in training set
Top 4%
1.0%
20
Journal of Experimental Medicine
● 119 papers in training set
Top 3%
1.0%
21
Cell Death Discovery
○ 58 papers in training set
Top 1%
1.0%
22
Communications Biology
○ 993 papers in training set
Top 27%
1.0%
23
Science Advances
● 1243 papers in training set
Top 31%
0.8%
24
Life Science Alliance
● 285 papers in training set
Top 8%
0.8%
25
Cancer Cell
○ 42 papers in training set
Top 2%
0.6%
26
Molecular Pharmacology
○ 17 papers in training set
Top 0.3%
0.6%
27
JCI Insight
● 277 papers in training set
Top 9%
0.6%
28
The EMBO Journal
○ 309 papers in training set
Top 8%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.